In Q2 2023, Eventide Asset Management held 92 positions worth $3.7B. They initiated 12 new positions and exited 23. Their largest holding was ZNTL ($194.0M). Portfolio value grew +1.2% versus the prior quarter.
Frequently asked questions
What stocks did Eventide Asset Management own in Q2 2023?
Eventide Asset Management held 92 biotech stocks in their 13F portfolio in Q2 2023. Their top positions include ZNTL, PANW, EXAS, TT, GH. The full holdings table is available on BiotechEdge with position sizes, quarter-over-quarter changes, and AI analysis.
How much was Eventide Asset Management's portfolio worth in Q2 2023?
Eventide Asset Management's tracked biotech portfolio was worth $3.7B across 92 positions, with total assets under management of approximately $6B. Portfolio values are based on 13F filings with the SEC.
What did Eventide Asset Management buy in Q2 2023?
Eventide Asset Management initiated 12 new positions in Q2 2023, including TOST, ALKS, FANG, MSCI, DVAX and 7 more. They also increased 33 existing positions.
What did Eventide Asset Management sell in Q2 2023?
Eventide Asset Management fully exited 23 positions in Q2 2023, including GTM, ZTS, ZIP, WEC, SYY and 18 more. They also trimmed 20 existing positions.
Is Eventide Asset Management a biotech fund?
Values-based investment firm with significant biotech allocation. Kuruvilla—a physician, engineer, and PhD—leads a team that evaluates companies on both financial merit and alignment with ethical principles. Known for holding high-conviction biotech positions alongside broader healthcare and technology investments.
Want AI analysis, insider signals, and catalyst overlays for Eventide Asset Management?
View latest Eventide Asset Management portfolio →